# Artesunate

Section: 6. Anti-infective medicines > 6.5. Antiprotozoal medicines > 6.5.3. Antimalarial medicines > 6.5.3.1. Antimalarial medicines > Medicines for curative treatment

**EMLc** Codes ATC: P01BE03

| | |
|---|---|
| **Indication** | Malaria due to Plasmodium vivax Code ICD11: 1F41 |
| **INN** | Artesunate |
| **Type de médicament** | Chemical agent |
| **Type de liste** | Liste de base |
| **Additional notes** | For use in the management of severe malaria |
| **Formulations** | **Parenteral > General injections > IV:** 60 mg in vial powder for injection ; 30 mg in vial powder for injection ; 120 mg in vial powder for injection<br>**Local > Rectal > Other:** 100 mg capsules (EMLc) |
| **Historique des statuts LME** | Ajouté pour la première fois en 1999 (TRS 895)<br>Modifié en 2002 (TRS 914)<br>Modifié en 2007 (TRS 946)<br>Modifié en 2007 (TRS 950)<br>Modifié en 2017 (TRS 1006)<br>Modifié en 2025 (TRS 1064) |
| **Sexe** | Tous |
| **Âge** | Aussi recommandé pour les enfants |
| **Équivalence thérapeutique** | La recommandation concerne ce médicament spécifique |
| **Renseignements sur le brevet** | Patents have expired in most jurisdictions<br>Lire la suite sur les brevets. |
| **Wikipédia** | Artesunate |
| **DrugBank** | Artesunate |

## Résumé des preuves et recommandation du comité d'experts

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of artesunate powder for injection 30 mg, 60 mg and 120 mg on the EML and EMLc; - the deletion of the previously listed injection formulation of artesunate from the EML and EMLc; - the deletion of 50 mg and 200 mg artesunate rectal capsules from the EML and EMLc; - the deletion of 50 mg artesunate tablets from the EML and EMLc. - the removal of footnotes regarding follow-up care and combination use.